Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.

In conclusion, eltrombopag treatment shortened the time to recovery from platelet nadir in patients treated with gemcitabine-based chemotherapy and reduced dose delays/reductions due to thrombocytopenia. PMID: 28864871 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28864871?dopt=Abstract

Source: International Journal of Hematology - September 1, 2017 Category: Hematology Authors: Winer ES, Safran H, Karaszewska B, Bauer S, Khan D, Doerfel S, Burgess P, Kalambakas S, Mostafa Kamel Y, Forget F Tags: Int J Hematol Source Type: research

More News: Anemia | Chemotherapy | Hematology | Study | Thrombocytopenia